BioArctic 股價因與百時美施貴寶在阿茲海默症領域的合作而飆升 27%

瑞典生技公司 BioArctic AB 宣布與美國製藥巨頭百時美施貴寶 (BMS) 達成重大合作後，其股價週四飆升超過 27%。

BioArctic AB (publ) (STO:BIOA B) stock soared on Thursday after the Swedish biotech firm announced a major collaboration with U.S. pharmaceutical giant Bristol Myers Squibb (NYSE:BMY).

BioArctic AB (publ) (STO:BIOA B) 股價週四飆升，此前這家瑞典生物技術公司宣布與美國製藥巨頭百時美施貴寶 (Bristol Myers Squibb) (NYSE:BMY) 進行重大合作。

The partnership will center on two of BioArctic's next-generation Alzheimer's disease programs, BAN1503 and BAN2803.

此次合作將集中在 BioArctic 的兩個下一代阿茲海默症計畫 BAN1503 和 BAN2803 上。

Of particular note is the incorporation of BioArctic's cutting-edge brain transporter technology (BTT) in BAN2803.

特別值得注意的是 BAN2803 中融入了 BioArctic 的尖端腦轉運技術 (BTT)。

According to RBC Capital Markets analysts, BTT is a potentially transformative method for targeting amyloid beta plaques in the brain, a key factor in Alzheimer's progression.

加拿大皇家銀行資本市場分析師表示，BTT 是一種潛在的變革性方法，可針對大腦中的β澱粉樣蛋白斑塊，而β澱粉樣蛋白斑塊是阿茲海默症進展的關鍵因素。

The collaboration will see BMS pay BioArctic an upfront sum of $100 million, with the possibility of an additional $1.25 billion in milestone payments if the projects achieve key developmental and commercial targets.

在此次合作中，BMS 將向 BioArctic 支付 1 億美元的預付款，如果專案實現關鍵的開發和商業目標，還可能額外支付 12.5 億美元的里程碑付款。

Furthermore, BioArctic is set to receive low double-digit royalties on future sales if the programs are successful in reaching the market.

此外，如果這些項目成功進入市場，BioArctic 將在未來銷售中獲得兩位數的低特許權使用費。

This partnership is being seen as a major validation of BioArctic's technology, especially its BTT platform, which is designed to improve the delivery and safety profile of Alzheimer's treatments.

此次合作被視為對 BioArctic 技術的重大驗證，尤其是其 BTT 平台，該平台旨在改善阿茲海默症治療的交付和安全性。

RBC analysts noted that while BioArctic's technology lags behind Roche's trontinemab by a few years, the backing of BMS could allow the company to accelerate the development of its programs and potentially offer a best-in-class solution.

RBC 分析師指出，雖然 BioArctic 的技術落後於羅氏的 trontinemab 幾年，但 BMS 的支援可以使該公司加速其專案的開發，並有可能提供一流的解決方案。

One of BioArctic's major innovations is targeting pyroglutamate amyloid beta subtypes, which are highly prone to aggregation and contribute to the formation of harmful plaques in Alzheimer's patients.

BioArctic 的主要創新之一是針對焦谷氨酸澱粉樣蛋白 β 亞型，極易聚集並導致阿茲海默症患者形成有害斑塊。

RBC analysts believe that this focus, combined with the delivery advantages of the BTT platform, could give BioArctic treatments a competitive edge over existing therapies.

RBC 分析師認為，這一重點與 BTT 平台的交付優勢相結合，可以使 BioArctic 療法比現有療法更具競爭優勢。

With BMS's resources and expertise now backing BioArctic's work, the company is poised to challenge larger players in the Alzheimer's treatment market.

現在，憑藉 BMS 的資源和專業知識支持 BioArctic 的工作，該公司已準備好挑戰阿茲海默症治療市場上更大的參與者。

BioArctic stock closed at SEK 170.00 on Thursday, reflecting a sharp increase in investor confidence.

BioArctic 股票週四收在 170.00 瑞典克朗，反映出投資者信心急劇增強。

RBC Capital Markets maintained its “Outperform” rating on the stock, setting a price target of SEK 340.00, citing the collaboration's potential to create long-term value.

加拿大皇家銀行資本市場維持對該股的「跑贏大盤」評級，設定目標價為 340.00 瑞典克朗，理由是此次合作有創造長期價值的潛力。